Criteria for Abstract Submission
• Abstracts must focus on scientific questions, device/delivery observations, or primary scientific data
• To minimize commercial bias, abstracts must not include company logos, names, or proprietary drug names
• Only the first author may submit requests. Submissions from co-authors, or medical communication / PR companies will not be considered
• First authors may submit up to two abstracts. If both are accepted, an alternate presenter must be appointed for one of the posters
• No revisions to abstracts will be allowed after the submission deadline

Abstract Format
Abstracts Must Contain the Following
• Data: Including all research information either in paragraph format or in charts and graphs ​​​​
• Title: In headline style: 200-character limit with no period at the end
• Authors: Limit of 12 authors
• Affiliations: One affiliation per author
• Purpose: In paragraph format
• Methods: In paragraph format
• Results: In paragraph format
• Conclusions: In paragraph format
• References: Reference any research previously published in a journal and used in the abstract’s research.
• Images: In jpg format, no more than three (3). Do not include images in the Purpose, Methods, Results, or Conclusions sections.
• Acknowledgements, disclaimers, funding and other disclosure or conflict of interest statements: This area should include any disclaimers, acknowledgements, funding, and other disclosure or conflict of interest statements, such as ethics approvals for animal use or human participation, which would prevent a blind review. This information will not be available to reviewers during the review process.

Abstract Length and Images
• Abstracts may contain a maximum of 800 words in the Purpose, Methods, Results, and Conclusion sections
• 1 to 3 images in jpg format may be included
• Data tables must be uploaded as one of three possible images and not included in the abstract text boxes

Late-Breaking Submission Criteria
Late-breaking submissions are allowed if they meet one of the following criteria:
• Results/Technologies were not available by the main deadline (July 21st, 2025)
• Groundbreaking findings that could significantly impact current delivery practices

To submit late-breaking data, provide a placeholder abstract by August 11th, 2025, including:
• All authors and their disclosures
• Background and methods sections
• Main clinical endpoint for your analysis
• Type of analysis, planned analysis date, and statistical methods

Submission Requirements
• Author Information: List full names, degrees, institutions, locations, and email addresses for all authors. The first author will receive all future correspondence. Up to 12 authors per abstract.
• Research Identification: Indicate if your abstract reports on original research or a drug delivery/device trial. For device trials, if already registered, provide the registry name and trial number. Registration is not required for submission but may be necessary by law for publication.
• Funding & Disclosures: Specify the funding source for the abstract, including any secondary sources. All authors must disclose financial ties with for-profit healthcare companies, which will be included in the meeting materials.